Business Wire

VIROMED-MEDICAL-AG

Share
Viromed Medical AG Seeks Special Approval for Cold Plasma Device for the Prevention of Ventilator-Associated Pneumonia (VAP)

Viromed Medical AG (ISIN: DE000A3MQR65; "Viromed") is launching a second pioneering study on the use of cold plasma for the prevention of ventilator-associated pneumonia (VAP). The study, under the scientific direction of Prof. Dr. Hortense Slevogt from the Hannover Medical School (MHH) and two other world-renowned institutes, aims to obtain rapid special approval for the PulmoPlas device developed by Viromed for this innovative preventive measure in Germany and the USA.

The further development and standardization of cold plasma technology for use in study-relevant cell cultures and later also in the human lung comes from relyon plasma GmbH, a wholly owned subsidiary of TDK Electronics AG. As a partner of Viromed, relyon plasma will establish the prototypes for the application and ensure the standardized generation of cold plasma as well as its characterization and consistency in the trial.

The exploitation rights are held by Viromed Medical AG.

VAP is a frequent and serious complication in mechanically ventilated patients. It occurs in patients who are invasively mechanically ventilated for at least 48 hours. Studies show that VAP occurs in 23 to 36 percent of mechanically ventilated patients and is associated with prolonged ventilation time and longer stays in the intensive care unit and hospital. The estimated mortality rate is 10 to 13 percent. In Germany alone, there were around 486,000 mechanically ventilated intensive care patients in 2023 and many thousands of deaths, with a strong upward trend. Many millions of patients worldwide are mechanically ventilated every year. The use of cold plasma against VAP would therefore have the potential to save hundreds of thousands of lives every year.

Uwe Perbandt, CEO of Viromed Medical AG: "The use of cold plasma has already proven very successful in the treatment of difficult-to-heal wounds. Our vision is to use the antimicrobial effect in other areas of application where treatment with conventional methods leads to unsatisfactory results. If several hundred thousand patients die from VAP every year, this is unacceptable. As a first mover, we are therefore systematically driving forward the relevant research and striving to obtain special approval for our PulmoPlas device as quickly as possible, as we see an urgent medical need for a better solution to the VAP problem. At the same time, we are tapping into an attractive market segment, as the global market for mechanical ventilation is predicted to see solid growth averaging 8.2% per year until 2032 due to the increase in chronic respiratory diseases."

Since October 2023, the MHH, in cooperation with Viromed Medical AG, has been investigating the safety profile of the use of cold plasma in bacterial infections of the respiratory tract using models of the respiratory mucosa. In particular, the focus is on the potential of cold plasma to kill bacteria that have infected the epithelium. In parallel, possibly associated inflammatory reactions, possible changes in cell differentiation, cell death, DNA damage as well as the therapeutic dose and the time window of application are being investigated. In order to optimize the effectiveness of different plasma compositions, their effectiveness in connection with cell damage will be investigated differentially. Due to promising preliminary results that have shown no damaging effect on the airway epithelium, a second study is now starting in parallel, which was originally planned for mid-2025. This will expand the investigation of the safety profile of cold plasma on alveolar epithelium, taking into account mechanical shear forces that act on the alveolar mucosa during breathing. In addition, the potential and safety of cold plasma to kill bacteria applied to precision-cut lung slices (PCLS) will be tested.

Prof. Dr. Hortense Slevogt, Clinic for Pneumology and Infectiology, MHH: "Ventilator-associated pneumonia not only has a high mortality rate, it is also a general burden on the healthcare system due to increased antibiotic consumption, longer patient stays and higher treatment costs. The increasing antibiotic resistance of pathogens also makes new, non-antibiotic approaches urgently necessary. If the positive preliminary results of our study continue to be confirmed and the safety of cold physical plasma in the human lung is established, cold plasma has the potential to revolutionize the treatment of ventilated patients."

About Viromed Medical AG:

Viromed Medical AG has a broad customer base in the DACH region, including various DAX companies, e.g. Volkswagen and Lufthansa, as well as federal states and various federal ministries, 1,100 hospitals, 7,000 pharmacies, and 17,000 medical practices.

Language: English
Company: Viromed Medical AG
Flensburger Straße 18
25421 Pinneberg
Germany
Phone: +49 4101 809960
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A3MQR65
WKN: A3MQR6
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg
EQS News ID:

1942511

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709060458/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CapVest and Parquest Agree Terms on IPN’s Acquisition of Sopral8.7.2025 10:00:00 CEST | Press release

Inspired Pet Nutrition (“IPN”), the fast-growing pet food company controlled by CapVest Partners LLP (“CapVest”), and Parquest, a leading investment firm, have agreed terms on the acquisition of Sopral, a prominent branded pet food platform serving the European market, with manufacturing operations based in France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250708134461/en/ Sopral products The transaction is subject to customary regulatory approvals and closing conditions. Financial terms have not been disclosed. Based in Pléchâtel, Brittany, France, Sopral is a leading manufacturer of branded premium dry petfood with a comprehensive range of high-quality nutritional solutions, including Pro-Nutrition Prestige, Pure Life and Protect brands. Sopral has a strong footprint and reputation in France and a fast growing online and international market presence in over 50 countries around the world. Employing over 130 people, th

Thales Reinforces its Leadership in eSIM and IoT Connectivity with a ‘Ready to Use’ Certified Solution8.7.2025 08:00:00 CEST | Press release

At a time when billions of connected objects are reshaping industries, Thales has achieved an essential security certification for its eSIM solution, reinforcing its leadership in trusted connectivity management for the Internet of Things (IoT). The certification, granted by the GSMA under the eSIM Security Assurance (eSA) scheme, marks a significant milestone in enabling large-scale, secure, and efficient IoT deployments across industries including smart metering, healthcare, and automotive. This positions Thales as a trusted partner capable of providing full protection against advanced cyber threats — delivering end-to-end security solutions, from chip to cloud, and ensuring compliance with emerging security standards (e.g., the EU Cyber Resilience Act). With over 5.8 billion IoT cellular connections expected globally by 2030 (GSMA Intelligence), businesses and industries face growing pressure to deploy connected devices at scale — securely and efficiently. The SGP.32 IoT specificati

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial8.7.2025 06:00:00 CEST | Press release

Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Through this collaboration, LabPMM (Invivoscribe’s global reference laboratories) have customized their multiparametric flow cytometry (MFC) services and implemented their sensitive MFC AML MRD assay to supportCERo’s clinical trial of its lead compound, CER-1236. The trial targets Acute Myeloid Leukemia (AML) in patients who are relapsed/refractory, in remission with MRD, or newly diagnosed with TP53-mutated MDS/AML. AML is an aggressive blood cancer characterized by the rapid accumulation of abnormal myeloid cells in the bone marrow and blood, disrupting normal hematopoiesis.1 Treating AML is especially complex due to its genetic heterogeneity and the high risk of relapse. CAR-T (chime

Tigo Energy Adds Solar-Plus-Storage Portfolio in Czech Republic to Build on MLPE Success8.7.2025 06:00:00 CEST | Press release

Successful PPDS P4 protocol certification opens full range of three-phase Tigo EI Inverters and the EI Residential product suite for grid connection in second-strongest E.U. market for Tigo. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company’s entire portfolio of three-phase Tigo EI Inverters has successfully passed the certification tests for compliance with the PPDS P4 requirements in the Czech Republic. Compliance with PPDS P4, formally known as Distribution System Operation Rules, Annex 4, is a prerequisite for grid connection of solar inverters in the Czech Republic, validating the compatibility with the technical conditions defined by the European Commission and adopted by local utility companies. In the wake of the proliferation of rapid shutdown requirements across Europe, with installers in the Czech Republic deploying nearly 107MW of Tigo MLPE in 2024, Tigo products ha

Murata Launches World’s First High-Frequency Filter Using XBAR Technology for 5G, Wi-Fi 7, and Future 6G Networks8.7.2025 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has announced the mass production and commercial shipment of the world’s first*1 high-frequency filter using XBAR technology*2. Developed by combining Murata’s proprietary Surface Acoustic Wave (SAW) filter expertise with XBAR technology from Murata's subsidiary Resonant Inc., it enables the extraction of desired signals while achieving both low insertion loss and high attenuation. These features are critical for the latest wireless technologies, including 5G, Wi-Fi 6E, Wi-Fi 7, and emerging 6G technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250707682186/en/ [Murata Manufacturing Co., Ltd.] The world’s first high-frequency filter using XBAR technology The demand for reliable high-frequency communications continues to grow in response to the widespread deployment of 5G and the future development of 6G. Simultaneously, wireless local-area network (W

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye